Company intelligence / Profile preview

Elusys Therapeutics

Parsippany, New Jersey, United Stateselusys.com ↗

Ownership: Private
Development stage: Commercial

Overview

ANTHIM® (obiltoxaximab), Elusys's lead product, is a monoclonal antibody antitoxin for inhalation anthrax. It received FDA approval in March 2016 and Health Canada approval in July 2020. ANTHIM is stockpiled as a medical countermeasure by the US government and has also been approved in the EU and UK under different trade names. The company has received substantial US government contracts for procurement and development of this product[1][5][9].

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

3 assets

obiltoxaximab

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Biomedical Advanced Research and Development Authority (BARDA)National Institute of Allergy and Infectious Disease (NIAID)Department of Defense (DoD)Public Health Agency of Canada

Beyond the preview

Go deeper on Elusys Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elusys Therapeutics.

Explore the full profile